Dr Peter Gough
NSF Health Sciences
Peter has 45 years’ experience of pharmaceutical manufacture, control and quality management. He has extensive experience of pharmaceutical law and in defining quality systems at a global level. He is a former member of EFPIA’s Manufacturing and GMP ad hoc group and was EFPIA topic leader on the ICH Expert Working Group which prepared the Q9 guideline on Quality Risk Management. Since the vote to leave the EU in June 2016, he has been providing regular commentary on the potential impacts of Brexit on the legal position for the supply of medicines in the UK and the EU. He is a Fellow of the Royal Society of Chemistry and of the UK Chartered Quality Institute (CQI) and is a former chairman of the CQI’s Pharmaceutical Quality Group.
- The Impact of Brexit on Pharmaceuticals
30 April 2019 2:50 pm